Viruses, Vol. 15, Pages 720: Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
In conclusion, our data on more than 4400 PWH show that adverse events have represented the most frequent cause of treatment interruptions in the first year of ART (3.84%). Treatment discontinuations were more frequent during the first year of follow-up and decreased thereafter. First-generation PI in both naïve and experienced PWH, and EVG/c, in experienced PWH, were associated with a higher risk of treatment interruptions. (Source: Viruses)
Source: Viruses - March 10, 2023 Category: Virology Authors: Andrea De Vito Elena Ricci Barbara Menzaghi Giancarlo Orofino Canio Vito Martinelli Nicola Squillace Lucia Taramasso Giuseppe Vittorio De Socio Chiara Molteni Laura Valsecchi Cecilia Costa Benedetto Maurizio Celesia Giustino Parruti Giovanni Francesco Pel Tags: Article Source Type: research
Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis
AIDS Research and Human Retroviruses, Ahead of Print. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - February 15, 2023 Category: Infectious Diseases Authors: Lorna Leal Alberto C. Guardo Luis M. Bedoya Cristina Rodr íguez de Miguel N úria Climent Cristina Rovira Manuela Beltr án Josep Llach Jose Alcam í Angela D.M. Kashuba Jose M. Gatell Montserrat Plana Felipe Garc ía Source Type: research
Chemical scaffold recycling: Structure-guided conversion of an HIV integrase inhibitor into a potent influenza virus RNA-dependent RNA polymerase inhibitor designed to minimize resistance potential
Eur J Med Chem. 2022 Dec 22;247:115035. doi: 10.1016/j.ejmech.2022.115035. Online ahead of print.ABSTRACTInfluenza is one of the leading causes of disease-related mortalities worldwide. Several strategies have been implemented during the past decades to hinder the replication cycle of influenza viruses, all of which have resulted in the emergence of resistant virus strains. The most recent example is baloxavir marboxil, where a single mutation in the active site of the target endonuclease domain of the RNA-dependent-RNA polymerase renders the recent FDA approved compound ∼1000-fold less effective. Raltegravir is a first-...
Source: European Journal of Medicinal Chemistry - January 5, 2023 Category: Chemistry Authors: Peter J Slavish Maxime G Cuypers Mary Ashley Rimmer Alireza Abdolvahabi Trushar Jeevan Gyanendra Kumar Jamie A Jarusiewicz Sivaraja Vaithiyalingam Jeremy C Jones John J Bowling Jeanine E Price Rebecca M DuBois Jaeki Min Richard J Webby Zoran Rankovic Step Source Type: research
Chemical scaffold recycling: Structure-guided conversion of an HIV integrase inhibitor into a potent influenza virus RNA-dependent RNA polymerase inhibitor designed to minimize resistance potential
Eur J Med Chem. 2022 Dec 22;247:115035. doi: 10.1016/j.ejmech.2022.115035. Online ahead of print.ABSTRACTInfluenza is one of the leading causes of disease-related mortalities worldwide. Several strategies have been implemented during the past decades to hinder the replication cycle of influenza viruses, all of which have resulted in the emergence of resistant virus strains. The most recent example is baloxavir marboxil, where a single mutation in the active site of the target endonuclease domain of the RNA-dependent-RNA polymerase renders the recent FDA approved compound ∼1000-fold less effective. Raltegravir is a first-...
Source: European Journal of Medicinal Chemistry - January 5, 2023 Category: Chemistry Authors: Peter J Slavish Maxime G Cuypers Mary Ashley Rimmer Alireza Abdolvahabi Trushar Jeevan Gyanendra Kumar Jamie A Jarusiewicz Sivaraja Vaithiyalingam Jeremy C Jones John J Bowling Jeanine E Price Rebecca M DuBois Jaeki Min Richard J Webby Zoran Rankovic Step Source Type: research
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat project
CONCLUSIONS: Our data show that the current overall percentage of carotid impairments remains high. Colour-Doppler ultrasonography could play a pivotal role in identifying and quantifying atherosclerotic lesions among PLWH, even at a very premature stage, and should be included in the algorithms of comorbidity management of these patients.PMID:36451295 | DOI:10.1111/hiv.13448 (Source: Atherosclerosis)
Source: Atherosclerosis - December 1, 2022 Category: Cardiology Authors: Paolo Maggi Elena Delfina Ricci Camilla Muccini Laura Galli Benedetto Maurizio Celesia Sergio Ferrara Yara Salameh Rosa Basile Giovanni Di Filippo Francesco Taccari Alessandra Tartaglia Antonella Castagna Source Type: research
Pharmacokinetics, the immunological impact and the effect on HIV ex-vivo infectivity of maraviroc, raltegravir and lopinavir in MSM using Post-exposure Prophylaxis
AIDS Res Hum Retroviruses. 2022 Nov 23. doi: 10.1089/AID.2021.0232. Online ahead of print.ABSTRACTMost of the studies using the colorectal tissue explants challenge model have been conducted after one single-dose and before reaching a steady-state. We consider that longer exposure as in 28-day post-exposure prophylaxis (PEP) course and in an at-risk setting, such as after a sexual risk exposure to HIV could give us valuable information about these drugs. In a substudy we assessed pharmacokinetics, changes on immune system and ex-vivo rectal mucosal susceptibility to HIV-1 infection after taking maraviroc (MVC), raltegravir...
Source: Cell Research - November 23, 2022 Category: Cytology Authors: Lorna Leal Alberto C Guardo Luis Miguel Bedoya Cristina Rodr íguez de Miguel Nuria Climent Cristina Rovira Manuela Beltr án Josep Llach Jose Alcami Angela Kashuba Jos é María Gatell Montserrat Plana Felipe Garc ía Source Type: research
Viruses, Vol. 14, Pages 2591: Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
elelis
Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency virus (HIV) infections. Raltegravir (RAL) and Elvitegravir (EVG), the first generation of INSTIs used successfully in clinical treatment, are susceptible to the emergence of viral resistance and have a high rate of cross-resistance. To counteract these resistant mutants, second-generation INSTI drugs have been developed: Dolutegravir (DTG), Cabotegravir (CAB), and Bictegravir (BIC). However, HIV is also able to develop resistance mechanisms against the second-generation of INS...
Source: Viruses - November 22, 2022 Category: Virology Authors: Richetta Tu Delelis Tags: Review Source Type: research
